Bristol-Myers signs deal with U.N. group for generic hepatitis C drug

(Reuters) – A United Nations-backed organization working to cut the price of HIV drugs said it had signed a deal with Bristol-Myers Squibb Co to allow generic versions of the company’s hepatitis C drug to be sold in 112 low- and middle-income countries. The drug, Daklinza, is on the World Health Organization’s list of essential medicines. Hepatitis C affects about 150 million people globally and kills around half a million each year, the World Health Organisation estimates.
Sexual Health News Headlines – Yahoo! News